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CASE

REPORT

Infusion reaction to infliximab biosimilar
after transitioning from infliximab
Reem Kashlan, MPH,a Alexis B. Lyons, MD,b Shanthi Narla, MD,b and Iltefat H. Hamzavi, MDb
Detroit, Michigan
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INTRODUCTION
Infliximab (IFX) (Remicade, Janssen Biotech Inc.,
Horsham, Pennsylvania) is a monoclonal antibody
against tumor necrosis factor-alpha. It is currently
approved by the United States Food and Drug
Administration for treating rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis, plaque
psoriasis, and inflammatory bowel disease.
Recently, it has also been used as an off-label
treatment for hidradenitis suppurativa (HS). Grant
et al1 outlined a significant improvement in HS
disease severity among patients who received IFX
therapy. IFX biosimilars, including infliximab-dyyb
(Inflectra, Pfizer, New York City, New York), demonstrate a similar safety and efficacy profile as the
original IFX product in patients with a variety of
chronic inflammatory conditions.2-4 However, there
is a paucity of data examining patients, including
those with HS, and how they responded to the IFX
biosimilar in comparison with how they responded
to IFX, especially with regard to side-effects data. We
present a case report of a patient who experienced
an infusion reaction after switching from IFX to the
biosimilar.

CASE REPORT
A 50-year-old Black woman with a past medical
history significant for diabetes mellitus and morbid
obesity presented for management of her HS. HS was
Hurley stage III and predominantly affected the
groin and buttocks. Prior and current treatments for
HS included neodymium-doped yttrium aluminum
garnet laser, wide local surgical excision, carbon
dioxide laser excision, various oral and intravenous
antibiotics, and IFX infusions. IFX was administered
at 5-8 mg/kg every 6 weeks for 7 years with good
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control of HS and no adverse reactions. However,
due to insurance coverage, the patient was switched
to the IFX biosimilar at 6 mg/kg every 6 weeks.
Within a few weeks of switching from IFX to the
biosimilar, the patient noticed the onset of minor
muscle aches and paresthesias, which would persist
for a couple of days following each infusion. The
severity of symptoms worsened with each subsequent infusion over 5 months with the eventual
development of full-body arthralgias and paresthesias affecting the hands. Antibodies against IFX were
obtained (from Mayo Clinic Laboratories, Rochester,
Minnesota) due to concern for worsening infusion
reactions and were elevated at 946 U/mL (reference
value \ 50 U/mL). The patient experienced
anaphylaxis-like symptoms with her subsequent
infusion, including throat tightening with associated
nasal congestion and flu-like symptoms within
30 minutes of infusion initiation. The medication
was immediately discontinued, and administration
of an oral antihistamine led to resolution of the
symptoms. The patient was then switched back to
IFX, which she initially tolerated; however, she
started experiencing similar infusion reactions after
the second infusion. The patient was prescribed
acetaminophen, diphenhydramine, and prednisone
for preinfusion treatment and a 5-day course of
prednisone post infusion if she experienced a reaction during the treatment. However, even with the
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medications, she continued to experience significant
adverse side effects. Currently, she is in the process
of switching biologics, given her continued infusion
reaction symptoms to IFX.

DISCUSSION
The IFX biosimilars have been shown to be
noninferior to IFX in terms of efficacy for psoriasis
and other indications.2 Previous randomized
controlled trials have outlined a similar frequency
of adverse events between switching to an IFX
biosimilar or continuing treatment with IFX.3,4 In
contrast, here we report a case of an infusion
reaction after switching from IFX to a biosimilar in
a patient receiving treatment for HS, where IFX had
previously been tolerated well.
Infusion reactions are immunologic reactions
classified based on the timing and severity of
symptoms and are not uncommon with the administration of IFX. Immediate infusion reactions often
occur during or within 1-2 hours post infusion, while
delayed infusion reactions often occur [24 hours
after infusion.5 Nausea, vomiting, chest pain, and
dyspnea are common manifestations. The etiology of
these reactions is not entirely understood, but some
associations have been discovered. The presence of
antidrug antibodies (ADA) predicts the development
of these reactions among patients receiving IFX
infusions.6 ADA generally consists of immunoglobulin antibodies targeting the Fab fragment of the
medication.7 Consequently, ADA can increase
immunogenicity and, thus, adverse reactions, due
to the formation of IFX-ADA complexes, which
activate complement and subsequently lead to
infusion reactions.5
Aggregates form when 2 or more proteins
assemble into stable complexes triggered by environmental stressors such as heat, oxidizing substances, or a change in pH that causes structural
changes and subsequent protein misfolding or
alteration.8 The IFX biosimilar contains a slightly
higher level of aggregates than IFX, which increases
immunogenicity, and has been implicated in eliciting
immune responses and infusion reactions.5,9 Further,
these insoluble aggregates can inherently illicit an
immune response via dendritic cell activation and
subsequent cytokine release.8 Triggering these adaptive immune responses enhance the production of
ADA, which further increases immunogenicity.8
Previous studies have outlined that antibodies to
IFX can recognize and crossreact with the IFX
biosimilar and vice versa, indicating immunogenic
similarity and sharing of immunodominant epitopes
between these 2 agents.7 Additionally, it has been
found that in patients being treated for rheumatoid
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arthritis, the presence of ADA to IFX increases the
likelihood of developing ADA to adalimumab and,
subsequently, to other biologics.10 Thus, the development of additional ADA specific to IFX after
switching from the biosimilar would be likely.
These differences could explain why this patient
developed a reaction to the biosimilar after switching
from IFX and why the infusion reaction was sustained after switching back from the biosimilar.
In conclusion, we report a case of an infusion
reaction following a switch from IFX to a biosimilar
in a patient with HS. When switching from IFX to
biosimilars, even if IFX was previously tolerated,
clinicians should be aware and should monitor for
symptoms of infusion reactions. These reactions
have also been reported with IFX infusions after
patients have tolerated treatment for several years.
However, the sudden onset of an infusion reaction is
an event that should be evaluated. Further studies
are needed to elucidate these reactions’ exact etiologies, develop appropriate preventative testing, and
optimize patient selection. These must be balanced
against the public health need for cost-effective
treatment options for HS.
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